These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 18482691

  • 21. A new class of peptidomimetics targeting the polo-box domain of Polo-like kinase 1.
    Ahn M, Han YH, Park JE, Kim S, Lee WC, Lee SJ, Gunasekaran P, Cheong C, Shin SY, Kim HY, Ryu EK, Murugan RN, Kim NH, Bang JK.
    J Med Chem; 2015 Jan 08; 58(1):294-304. PubMed ID: 25347203
    [Abstract] [Full Text] [Related]

  • 22. Polo and Aurora kinases: lessons derived from chemical biology.
    Taylor S, Peters JM.
    Curr Opin Cell Biol; 2008 Feb 08; 20(1):77-84. PubMed ID: 18249108
    [Abstract] [Full Text] [Related]

  • 23. A pan-specific inhibitor of the polo-box domains of polo-like kinases arrests cancer cells in mitosis.
    Reindl W, Yuan J, Krämer A, Strebhardt K, Berg T.
    Chembiochem; 2009 May 04; 10(7):1145-8. PubMed ID: 19350612
    [Abstract] [Full Text] [Related]

  • 24. Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity.
    Johnson EF, Stewart KD, Woods KW, Giranda VL, Luo Y.
    Biochemistry; 2007 Aug 21; 46(33):9551-63. PubMed ID: 17655330
    [Abstract] [Full Text] [Related]

  • 25. Small-molecular, non-peptide, non-ATP-competitive polo-like kinase 1 (Plk1) inhibitors with a terphenyl skeleton.
    Mita Y, Noguchi-Yachide T, Ishikawa M, Hashimoto Y.
    Bioorg Med Chem; 2013 Feb 01; 21(3):608-17. PubMed ID: 23276450
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Design, synthesis and evaluation of d-amino acid-containing peptidomimetics targeting the polo-box domain of polo-like kinase 1.
    Li Z, Zhang Z, Chen Y, Tang S, Lin T, Huang J, Li B, Jiang C.
    Bioorg Chem; 2019 Apr 01; 85():534-540. PubMed ID: 30807896
    [Abstract] [Full Text] [Related]

  • 32. Phosphopeptides with improved cellular uptake properties as ligands for the polo-box domain of polo-like kinase 1.
    Richter S, Neundorf I, Loebner K, Gräber M, Berg T, Bergmann R, Steinbach J, Pietzsch J, Wuest F.
    Bioorg Med Chem Lett; 2011 Aug 15; 21(16):4686-9. PubMed ID: 21778054
    [Abstract] [Full Text] [Related]

  • 33. Identification of a high affinity selective inhibitor of Polo-like kinase 1 for cancer chemotherapy by computational approach.
    Kumar M, Pydi SP, Sharma S, Singh TP, Kaur P.
    J Mol Graph Model; 2014 Jun 15; 51():104-12. PubMed ID: 24879322
    [Abstract] [Full Text] [Related]

  • 34. Novel Macrocyclic Peptidomimetics Targeting the Polo-Box Domain of Polo-Like Kinase 1.
    Ryu S, Park JE, Ham YJ, Lim DC, Kwiatkowski NP, Kim DH, Bhunia D, Kim ND, Yaffe MB, Son W, Kim N, Choi TI, Swain P, Kim CH, Lee JY, Gray NS, Lee KS, Sim T.
    J Med Chem; 2022 Feb 10; 65(3):1915-1932. PubMed ID: 35029981
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Development of high-throughput assays based on fluorescence polarization for inhibitors of the polo-box domains of polo-like kinases 2 and 3.
    Reindl W, Gräber M, Strebhardt K, Berg T.
    Anal Biochem; 2009 Dec 15; 395(2):189-94. PubMed ID: 19716361
    [Abstract] [Full Text] [Related]

  • 37. Design, synthesis and biological evaluation of phosphopeptides as Polo-like kinase 1 Polo-box domain inhibitors.
    Lin TY, Min HP, Jiang C, Niu MM, Yan F, Xu LL, Di B.
    Bioorg Med Chem; 2018 Jul 23; 26(12):3429-3437. PubMed ID: 29807699
    [Abstract] [Full Text] [Related]

  • 38. Structure-Based Virtual Screening and Biological Evaluation of Peptide Inhibitors for Polo-Box Domain.
    Yan F, Liu G, Chen T, Fu X, Niu MM.
    Molecules; 2019 Dec 27; 25(1):. PubMed ID: 31892137
    [Abstract] [Full Text] [Related]

  • 39. Targeting polo-like kinase: learning too little too late?
    Olmos D, Swanton C, de Bono J.
    J Clin Oncol; 2008 Dec 01; 26(34):5497-9. PubMed ID: 18955441
    [No Abstract] [Full Text] [Related]

  • 40. Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibition.
    Kreis NN, Louwen F, Zimmer B, Yuan J.
    Oncotarget; 2015 Mar 30; 6(9):6611-26. PubMed ID: 25483104
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.